AstraZeneca, Pozen deal

AZN and POZN changed the milestone and royalty terms of a 2006 deal to co-develop and commercialize fixed-dose combinations of esomeprazole plus naproxen using POZN's PN formulation technology (see BioCentury, Aug. 7, 2006). POZN will immediately receive $10 million for the amendment and a $20 million milestone payment. The company is now eligible for $55 million in development and regulatory milestones, plus $260 million in sales milestones. Previously, the milestones were weighted more toward development and regulatory than toward sales ($160 million and $175 million, respectively). ...